ChAdOx1新型冠状病毒疫苗对B.1.351变异株的有效性。回复。 - Suppr

Suppr

超能文献

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.

作者信息

Madhi Shabir A, Izu Alane, Pollard Andrew J

机构信息

University of the Witwatersrand, Johannesburg, South Africa.

University of Oxford, Oxford, United Kingdom.

出版信息

N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.

DOI:10.1056/NEJMc2110093

PMID:34289271

Abstract

摘要

相似文献

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.ChAdOx1新型冠状病毒疫苗对B.1.351变异株的有效性。回复。

N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.ChAdOx1新冠疫苗对B.1.351变种的有效性

N Engl J Med. 2021 Aug 5;385(6):571. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.

Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.假说：抗载体免疫和 SARS-CoV-2 变体对 ChAdOx1 nCoV-19 疫苗效力的可能影响。

Br J Pharmacol. 2022 Jan;179(2):218-226. doi: 10.1111/bph.15620. Epub 2021 Jul 31.

Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.12 剂小瓶 ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 的免疫原性：一项中期分析。

Vaccine. 2022 Jan 28;40(4):587-593. doi: 10.1016/j.vaccine.2021.12.023. Epub 2021 Dec 22.

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).泰国家庭中灭活 SARS-CoV-2 疫苗和 ChAdOx1 nCoV-19 疫苗接种预防 COVID-19 的效果（VacPrevent 试验）。

Int J Infect Dis. 2022 Nov;124:190-198. doi: 10.1016/j.ijid.2022.09.032. Epub 2022 Sep 28.

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.异源 ChAdOx1-nCoV-19/mRNA-1273 疫苗接种与同源 ChAdOx1-nCoV-19 或同源 mRNA-1273 疫苗接种的免疫反应和安全性比较。

J Formos Med Assoc. 2022 Apr;121(4):766-777. doi: 10.1016/j.jfma.2022.02.020. Epub 2022 Mar 16.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.《6-17 岁儿童中 ChAdOx1 nCoV-19（AZD1222）疫苗的安全性和免疫原性：COV006 的初步报告，一项 2 期、单盲、随机、对照试验》

Lancet. 2022 Jun 11;399(10342):2212-2225. doi: 10.1016/S0140-6736(22)00770-X.

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.鼻内接种腺病毒载体 COVID-19 疫苗的耐受性和免疫原性：一项开放性、部分随机、递增剂量的 I 期临床试验。

EBioMedicine. 2022 Nov;85:104298. doi: 10.1016/j.ebiom.2022.104298. Epub 2022 Oct 10.

Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.腺病毒载体 ChAdOx1 nCoV-19 疫苗接种后引发浅静脉血栓形成：两例病例报告

J Med Case Rep. 2022 May 7;16(1):182. doi: 10.1186/s13256-022-03407-6.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）接种后发生急性脱髓鞘性多发神经根神经病伴双侧面瘫 1 例。

Neurol Sci. 2021 Nov;42(11):4747-4749. doi: 10.1007/s10072-021-05467-w. Epub 2021 Jul 17.

引用本文的文献

Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2.靶向 SARS-CoV-2 中的抗病毒 N 蛋白抑制剂与蛋白-蛋白相互作用界面。

Biophys J. 2024 Feb 20;123(4):478-488. doi: 10.1016/j.bpj.2024.01.013. Epub 2024 Jan 17.

Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor.结构、动力学及点突变对 SARS-CoV-2 刺突蛋白与 ACE2 受体结合影响的自由能研究。

PLoS One. 2023 Oct 5;18(10):e0289432. doi: 10.1371/journal.pone.0289432. eCollection 2023.

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.在博茨瓦纳接种ChAdOx1（AZD1222）新冠疫苗后新冠病毒病的安全性及发病率

J Infect. 2023 Jun;86(6):603-606. doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1.

Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant.自然获得和疫苗诱导的针对 SARS-CoV-2 Mu 变异株的免疫反应的有效性。

Emerg Infect Dis. 2022 Aug;28(8):1708-1712. doi: 10.3201/eid2808.220584. Epub 2022 Jul 13.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在非洲：当前的考虑因素和未来的预测。

Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S136-S140. doi: 10.1093/cid/ciac401.

Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19.医护人员接种科兴疫苗后唾液、血清和细胞免疫应答与既往 COVID-19 感染的关系。

Sci Rep. 2022 Jun 16;12(1):10125. doi: 10.1038/s41598-022-14283-x.

COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants.2019冠状病毒病疫苗及现有疫苗对2019冠状病毒病变体的效力

Cureus. 2022 May 11;14(5):e24927. doi: 10.7759/cureus.24927. eCollection 2022 May.

Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.新冠疫苗诱导的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的刺突蛋白特异性免疫的持久性

Biomedicines. 2022 Apr 26;10(5):996. doi: 10.3390/biomedicines10050996.

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.三种 SARS-CoV-2 抗体对包括奥密克戎在内的关注变种提供广泛且协同的中和作用。

Cell Rep. 2022 May 24;39(8):110862. doi: 10.1016/j.celrep.2022.110862. Epub 2022 May 8.

Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children.儿童严重急性呼吸综合征冠状病毒 2 感染的病毒学特征。

J Infect Dis. 2021 Dec 1;224(11):1821-1829. doi: 10.1093/infdis/jiab509.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验